Nucleus is a venture studio that launches, acquires, and partners with assets that create meaningful connections between people and the wellness industry.
At the core of everything we do is Neuly—our proprietary data platform that powers all Nucleus brands. This centralized approach allows us to build, scale, and connect our portfolio companies with unprecedented efficiency.
Each spoke in our ecosystem serves a unique purpose: from research and education to clinical tools and consumer platforms. Together, they form a comprehensive network addressing every stakeholder in the mental wellness space.
Nucleus values synergies. Partners can form strategic alliances with any of the Nucleus entities through data/content distribution and customer activation.
Via Nucleus's API, third parties can leverage industry data and connect their own data to our proprietary technology to offer even more insights for users.
Through our public-facing entities, Nucleus aspires to help people connect and build on top of its ecosystem, creating lasting impact.
In April of 2021, we co-founded Iter Investments—a venture capital fund investing in companies focused on psychedelic medicine. Our investment team realized very quickly that within the industry there was a lack of connection between the "industry" and "the people."
We saw this gap as a major hindrance to the progression of psychedelics and their foreseeable impact on billions of lives. This is where Nucleus comes in.
Nucleus was founded as a venture studio that launches, acquires, or partners with assets that create the much-needed connection between the people and the industry.
Co-Founder, Nucleus
Co-Founder, Iter Investments
"At Nucleus, we envision a world with unobstructed access to the most effective models of care."— The Nucleus Team
Get exclusive updates on our portfolio companies, industry insights, and opportunities to participate in the wellness revolution.